Dose escalation of an Evans blue–modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors | Zendy

Qingxing Liu | Zendy; Yuejuan Cheng | Zendy; Jie Zang | Zendy; Huimin Sui | Zendy; Hao Wang | Zendy; Orit Jacobson | Zendy; Zhaohui Zhu | Zendy; Xiaoyuan Chen | Zendy

Open Access

Dose escalation of an Evans blue–modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors

Author(s) -

Qingxing Liu,

Yuejuan Cheng,

Jie Zang,

Huimin Sui,

Hao Wang,

Orit Jacobson,

Zhaohui Zhu,

Xiaoyuan Chen

Publication year - 2019

Publication title -

european journal of nuclear medicine and molecular imaging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.313

H-Index - 163

eISSN - 1619-7089

pISSN - 1619-7070

DOI - 10.1007/s00259-019-04530-1

Subject(s) - medicine , neuroendocrine tumors , radionuclide therapy , nuclear medicine , somatostatin , octreotide , adverse effect , chemotherapy , response evaluation criteria in solid tumors , dota , urology , gastroenterology , progressive disease , chelation , chemistry , organic chemistry

To evaluate the safety and efficacy of 177 Lu-DOTA-EB-TATE, a radiolabeled somatostatin analog modified by Evans blue, at escalating doses, was used to increase tumor retention in patients with progressive metastatic neuroendocrine tumors (NETs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research